S&P Futures
5,902.00 +5.50 (+0.09%) Dow Futures
43,471.00 -97.00 (-0.22%) Nasdaq Futures
20,605.50 +111.75 (+0.55%) Russell 2000 Futures
2,318.30 +4.70 (+0.20%) Crude Oil
66.82 -0.20 (-0.30%) Gold
2,590.20 +20.10 (+0.78%)
IQV Dec 2024 350.000 call
| Previous Close | 4.0000 |
| Open | 3.8000 |
| Bid | 1.1000 |
| Ask | 1.4000 |
| Strike | 350.00 |
| Expire Date | 2024-12-20 |
| Day's Range | 4.0000 - 4.0000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 70 |
- Business Wire
IQVIA CFO Ron Bruehlman to Speak at the UBS Global Healthcare Conference on November 13, 2024
RESEARCH TRIANGLE PARK, N.C., November 06, 2024--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the UBS Healthcare Conference in Rancho Palos Verdes, California on Wednesday, November 13, 2024 at 1:15 p.m. ET.
TipRanksIqvia price target lowered to $265 from $280 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Iqvia (IQV) to $265 from $280 and keeps an Overweight rating on the shares. A “modest beat” in Q3 was led by better-than-expected TAS performance, but this is overshadowed by R&DS headwinds over the next twelve months, including a single large cancellation and two “mega trial delays” to 2025, the analyst tells investors in a post-earnings note. The firm views the risk/reward as attractive on the recent pullback, the analyst added. Published first
